- Acute herpes zoster:
- 500mg TDS *1/52
- 500mg TDS *1/52
- Genital herpes in immunocompetent patients:
- Initial episode: 250mg TDS *7-10 days
- May extend treatment if not healed after 10 days
- Initial episode: 250mg TDS *7-10 days
-
- Recurrent episodes: 1000mg BD*1/7
- Initiated within 6 hours of symptom or lesion onset
- Recurrent episodes: 1000mg BD*1/7
-
- Suppressive therapy: 250mg BD for 12 months
- Genital herpes in immunocompromised patients:
- Initial episode: 500mg BD *7-10 days
- Initiated within 48 hours of symptom or lesion onset
- Initial episode: 500mg BD *7-10 days
-
- Recurrent episodes: 500mg BD*5-10 days
- Initiated within 48 hours of symptom or lesion onset
- Recurrent episodes: 500mg BD*5-10 days
-
- Suppressive therapy: 500mg BD for 12 months
- Orolabial herpes in immunocompetent patients:
- Recurrent episodes: 1500mg *1
- Immediately after onset
- Recurrent episodes: 1500mg *1
- Orolabial herpes in immunocompromised patients:
- Initial episode: 500mg BD *5-10 days
- Initiated within 48 hours of symptom or lesion onset
- Initial episode: 500mg BD *5-10 days
-
- Recurrent episodes: 500mg BD*1/52
- Initiated within 48 hours of symptom or lesion onset
- Recurrent episodes: 500mg BD*1/52
-
- Suppressive therapy: 500mg BD for 12 months
- Tablet:
- 125mg
- 250mg
- 500mg
- 750mg
Taken without regards to meals
Antiviral
Prodrug of penciclovir. It inhibits DNA polymerase, selectively inhibiting herpes viral DNA synthesis and replication
- Headache
- Nausea
- Diarrhea
- Vomiting
- Fatigue
- Pruritus
- Neutropenia
- Abnormal LFTs
- Paresthesia
- Flatulence
- Hypersensitivity to class/components
- Varicella/zoster live vaccine
- Tamoligene
Drug Status
Availability | Prescription only |
Pregnancy | Category B |
Breastfeeding | Use with caution |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Penvir | 500mg | Tablet | 10’s | Hetero Labs | Unisel Ltd |